Antibiotic Exposure and Risk of Parkinson's Disease in Finland: A Nationwide Case‐Control Study
Open accessAbstract
Background: Gut microbiota alterations have been found in prodromal and established Parkinson's disease (PD). Antibiotic exposure can have long‐term effects on the composition of human intestinal microbiota, but a potential connection between antibiotic exposure and risk of PD has not been studied previously. Objective: To evaluate the impact of antibiotic exposure on the risk of PD in a nationwide, register‐based, case‐control study. Methods: We identified all patients who were diagnosed with PD in Finland during the years 1998 to 2014. Information was obtained on individual purchases of orally administered antibiotics during the years 1993 to 2014. We assessed the association between prior antibiotic exposure and PD using conditional logistic regression. Results: The study population consisted of 13,976 PD cases and 40,697 controls. The strongest connection with PD risk was found for oral exposure to macrolides and lincosamides (adjusted odds ratio up to 1.416; 95% confidence interval, 1.053–1.904). After correction for multiple comparisons, exposure to antianaerobics and tetracyclines 10 to 15 years before the index date, sulfonamides and trimethoprim 1 to 5 years before the index date, and antifungal medications 1 to 5 years before the index date were positively associated with PD risk. In post hoc analyses, further positive associations were found for broad‐spectrum antibiotics. Conclusions: Exposure to certain types of oral antibiotics seems to be associated with an elevated risk of PD with a delay that is consistent with the proposed duration of a prodromal period. The pattern of associations supports the hypothesis that effects on gut microbiota could link antibiotics to PD, but further studies are needed to confirm this. © 2019 International Parkinson and Movement Disorder Society
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Use of antibiotics-especially macrolides and lincosamides-is related to increased risk of PD.
“it has been reported that the use of antibiotics—especially macrolides and lincosamides—is related to the increased risk of PD [12].”
From Neuroprotective Effect of Ceftriaxone on MPTP‐Induced Parkinson’s Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota (2021) · cites this paper as [12]
A Finnish study on 13,976 PD and 40,697 healthy individuals showed that taking certain antibiotics years earlier, especially macrolides and lincosamides, correlates with an increased risk of developing PD.
“In humans, a Finnish study conducted on 13,976 PD and 40,697 healthy individuals showed that taking certain antibiotics years earlier, especially macrolides and lincosamides, correlates with an increased risk of developing PD [306].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [306]
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · see citing works
A Coefficient of Agreement for Nominal Scales
Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398 · see citing works
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320 · see citing works
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796 · see citing works
Role of the normal gut microbiota
Jandhyala, S. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i29.8787 · Cited by 3,001 · see citing works
New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality
Sundararajan, V., Henderson, T., Perry, C., Muggivan, A., Quan, H., & Ghali, W. A. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.03.012 · Cited by 2,439 · see citing works
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · see citing works
Self-citationKim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397 · see citing works
Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354 · see citing works
Quality of the Finnish Hospital Discharge Register: A systematic review
Sund, R. (2012) · Scandinavian Journal of Public Health · doi:10.1177/1403494812456637 · Cited by 1,190 · see citing works
Long-term impacts of antibiotic exposure on the human intestinal microbiota
Jernberg, C., Löfmark, S., Edlund, C., & Jansson, J. K. (2010) · Microbiology · doi:10.1099/mic.0.040618-0 · Cited by 1,067 · see citing works
Parkinson's disease: a dual‐hit hypothesis
Hawkes, C. H., Del Tredici, K., & Braak, H. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00874.x · Cited by 1,021 · see citing works
Adjust for multiple comparisons? It’s not that simple
Althouse, A. D. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.11.024 · Cited by 825 · see citing works
Effect of antimicrobial agents on the ecological balance of human microflora
Sullivan, Å., Edlund, C., & Nord, C. E. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00066-4 · Cited by 816 · see citing works
Vagotomy and subsequent risk of <scp>P</scp> arkinson's disease
Svensson, E., Horváth‐Puhó, E., Thomsen, R. W., Djurhuus, J. C., Pedersen, L., Borghammer, P., & Sørensen, H. T. (2015) · Annals of Neurology · doi:10.1002/ana.24448 · Cited by 806 · see citing works
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. E. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 772 · see citing works
Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease
Rocha, E. M., Miranda, B. D., & Sanders, L. H. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.04.004 · Cited by 769 · see citing works
Antibiotics as deep modulators of gut microbiota: between good and evil
Ianiro, G., Tilg, H., & Gasbarrini, A. (2016) · Gut · doi:10.1136/gutjnl-2016-312297 · Cited by 629 · see citing works
Heintz‐Buschart, A., Pandey, U., Wicke, T., Sixel‐Döring, F., Janzen, A., Sittig‐Wiegand, E., Trenkwalder, C., Oertel, W. H., Mollenhauer, B., & Wilmes, P. (2018) · Movement Disorders · doi:10.1002/mds.27105 · Cited by 554 · see citing works
Antibiotic Exposure and IBD Development Among Children: A Population-Based Cohort Study
Kronman, M. P., Zaoutis, T. E., Haynes, K., Feng, R., & Coffin, S. E. (2012) · PEDIATRICS · doi:10.1542/peds.2011-3886 · Cited by 445 · see citing works
Stokholm, M. G., Danielsen, E. H., Hamilton‐Dutoit, S. J., & Borghammer, P. (2016) · Annals of Neurology · doi:10.1002/ana.24648 · Cited by 415 · see citing works
The human mycobiome in health and disease
Cui, L., Morris, A., & Ghedin, E. (2013) · Genome Medicine · doi:10.1186/gm467 · Cited by 379 · see citing works
Knudsen, K., Fedorova, T. D., Hansen, A. K., Sommerauer, M., Otto, M., Svendsen, K. B., Nahimi, A., Stokholm, M. G., Pavese, N., Beier, C. P., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30162-5 · Cited by 309 · see citing works
Kelly, L. P., Carvey, P. M., Keshavarzian, A., Shannon, K. M., Shaikh, M., Bakay, R. A. E., & Kordower, J. H. (2014) · Movement Disorders · doi:10.1002/mds.25736 · Cited by 308 · see citing works
Uncovering effects of antibiotics on the host and microbiota using transkingdom gene networks
Morgun, A., Dzutsev, A., Dong, X., Greer, R. L., Sexton, D. J., Ravel, J., Schuster, M., Hsiao, W., Matzinger, P., & Shulzhenko, N. (2015) · Gut · doi:10.1136/gutjnl-2014-308820 · Cited by 304 · see citing works
Antibiotic Exposure and the Risk for Depression, Anxiety, or Psychosis: A Nested Case-Control Study
Lurie, I., Yang, Y.-X., Haynes, K., Mamtani, R., & Boursi, B. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m09961 · Cited by 231 · see citing works
Constipation preceding Parkinson's disease: a systematic review and meta-analysis
Adams-Carr, K. L., Bestwick, J. P., Shribman, S., Lees, A., Schrag, A., & Noyce, A. J. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311680 · Cited by 228 · see citing works
Feng, Y., Huang, Y., Wang, Y., Wang, P., Song, H., & Wang, F. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218384 · Cited by 225 · see citing works
Virta, L. J., Auvinen, A. P., Helenius, H. Y. M., Huovinen, P., & Kolho, K.-L. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kwr400 · Cited by 197 · see citing works
Temporal relationship between cigarette smoking and risk of Parkinson disease
Thacker, E. L., O’Reilly, É. J., Weisskopf, M. G., Chen, H., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2007) · Neurology · doi:10.1212/01.wnl.0000256374.50227.4b · Cited by 193 · see citing works
Inflammatory Bowel Disease and Parkinson’s Disease: A Nationwide Swedish Cohort Study
Weimers, P., Halfvarson, J., Sachs, M. C., Saunders-Pullman, R. J., Ludvigsson, J. F., Peter, I., Burisch, J. M., & Olén, O. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy190 · Cited by 173 · see citing works
The association between infectious burden and Parkinson's disease: A case-control study.
Bu, X.-L., Wang, X., Xiang, Y., Shen, L.-L., Wang, Q.-H., Liu, Y.-H., Jiao, S.-S., Wang, Y.-R., Cao, H.-Y., Yi, X., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.05.015 · Cited by 153 · see citing works
Mertsalmi, T. H., Aho, V. T. E., Pereira, P. A. B., Paulin, L., Pekkonen, E., Auvinen, P., & Scheperjans, F. (2017) · European Journal of Neurology · doi:10.1111/ene.13398 · Cited by 153 · cited 1× · see citing works
“In PD, several studies have described alterations of gut microbiota composition, and changes in fecal microbiota abundance have been found to be associated with gastrointestinal and motor symptoms.(17,18) However, the cause of these changes is not known.”
BackgroundSelf-citationExploring the Association Between Rosacea and Parkinson Disease
Egeberg, A., Hansen, P. R., Gislason, G., & Thyssen, J. P. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0022 · Cited by 119 · see citing works
Impact of antibiotic exposure on the risk of colorectal cancer
Boursi, B., Haynes, K., Mamtani, R., & Yang, Y. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3765 · Cited by 91 · see citing works
Irritable bowel syndrome correlates with increased risk of Parkinson’s disease in Taiwan
Lai, S., Liao, K., Lin, C.-L., & Sung, F. (2014) · European Journal of Epidemiology · doi:10.1007/s10654-014-9878-3 · Cited by 73 · see citing works
Sodhi, C. P., Rana, S. V., Mehta, S., Vaiphei, K., Attri, S. V., Thakur, S., & Mehta, S. (1996) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/(sici)1522-7146(1996)11:3 · Cited by 53 · see citing works
Gastric emptying in Parkinson's disease – A mini-review
Knudsen, K., Szwebs, M., Hansen, A. K., & Borghammer, P. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.06.003 · Cited by 49 · see citing works
Antibacterial Agents: Chemistry, Mode of Action, Mechanisms of Resistance and Clinical Applications
Anderson, R. J., Groundwater, P. W., Todd, A., & Worsley, A. J. (2012) · Durham Research Online (Durham University) · Cited by 37 · see citing works
Broad- and narrow-spectrum antibiotics: an unhelpful categorization
Acar, J. F. (1997) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.1997.tb00274.x · Cited by 33 · see citing works
Minocycline Protects Dopaminergic Neurons Against Long-Term Rotenone Toxicity
Radad, K., Moldzio, R., & Rausch, W.-D. (2010) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100009690 · Cited by 30 · see citing works
Protopathic bias in observational studies on statin effectiveness
Korhonen, M. J., Huupponen, R., Ruokoniemi, P. T., & Helin‐Salmivaara, A. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0701-0 · Cited by 9 · see citing works
Xu, K., Alnaji, N., Zhao, J., Bertoni, J. M., Chen, L., Bhatti, D., & Qu, M. (2017) · Neuroepidemiology · doi:10.1159/000484410 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Facchin, S., Bertin, L., Bonazzi, E., Lorenzon, G., Barba, C. D., Barberio, B., Zingone, F., Maniero, D., Scarpa, M., Ruffolo, C., et al. (2024) · Life · doi:10.3390/life14050559 · Cited by 422 · see citing works
de Nies, L., Lopes, S., Busi, S. B., Galata, V., Heintz‐Buschart, A., Laczny, C. C., May, P., & Wilmes, P. (2021) · Microbiome · doi:10.1186/s40168-020-00993-9 · Cited by 186 · see citing works
Parkinson's Disease: A Multisystem Disorder
Costa, H. N., Esteves, A. R., Empadinhas, N., & Cardoso, S. M. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00934-6 · Cited by 191 · see citing works
Bicknell, B. T., Liebert, A. D., Borody, T. J., Herkes, G., McLachlan, C. S., & Kiat, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119577 · Cited by 129 · see citing works
TLR2 and TLR4 in Parkinson’s disease pathogenesis: The environment takes a toll on the gut
Gorecki, A. M., Anyaegbu, C. C., & Anderton, R. S. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00271-0 · Cited by 103 · see citing works
Neurodegenerative disorders and gut-brain interactions
Singh, A., Dawson, T. M., & Kulkarni, S. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143775 · Cited by 102 · see citing works
Zhou, X., Lu, J., Wei, K., Wei, J., Tian, P., Yue, M., Wang, Y., Hong, D., Li, F., Wang, B., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9424582 · Cited by 85 · see citing works
Oral and Gut Dysbiosis Leads to Functional Alterations in Parkinson’s Disease
Jo, S., Kang, W., Hwang, Y. S., Lee, S. H., Park, K. W., Kim, M. S., Lee, H., Yoon, H. J., Park, Y. K., Chalita, M., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00351-6 · Cited by 85 · see citing works
Oral Dysbiosis and Inflammation in Parkinson’s Disease
Fleury, V., Zekeridou, A., Lazarević, V., Gaïa, N., Giannopoulou, C., Genton, L., Cancela, J., Girard, M., Goldstein, R., Bally, J. F., et al. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202459 · Cited by 91 · see citing works
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88 · see citing works
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside
Ma, Y., Li, X., Yu, J., & Wang, Y. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00404-1 · Cited by 87 · see citing works
Intestinal Inflammation and Parkinson’s Disease
Li, Y., Chen, Y., Jiang, L., Zhang, J., Tong, X., Chen, D., & Le, W. (2021) · Aging and Disease · doi:10.14336/ad.2021.0418 · Cited by 74 · see citing works
Role of the Exposome in Neurodegenerative Disease: Recent Insights and Future Directions
Sakowski, S. A., Koubek, E. J., Chen, K. S., Goutman, S. A., & Feldman, E. L. (2024) · Annals of Neurology · doi:10.1002/ana.26897 · Cited by 73 · see citing works
New hope for Parkinson’s disease treatment: Targeting gut microbiota
Fan, H., Sheng, S., & Zhang, F. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13916 · Cited by 66 · see citing works
The microbiota–gut–brain axis in Huntington's disease: pathogenic mechanisms and therapeutic targets
Ekwudo, M. N., Gubert, C., & Hannan, A. J. (2024) · FEBS Journal · doi:10.1111/febs.17102 · Cited by 60 · see citing works
Liang, Y., Cui, L., Gao, J., Zhu, M., Zhang, Y., & Zhang, H. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02375-0 · Cited by 59 · see citing works
Walker, A. C., Bhargava, R., Vaziriyan-Sani, A. S., Pourciau, C., Donahue, E. T., Dove, A. S., Gebhardt, M. J., Ellward, G. L., Romeo, T., & Czyż, D. M. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009510 · Cited by 54 · see citing works
Bacterial extracellular vesicles at the interface of gut microbiota and immunity
Melo-Marques, I., Cardoso, S. M., & Empadinhas, N. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2396494 · Cited by 59 · see citing works
Environmental triggers of Parkinson's disease – Implications of the Braak and dual-hit hypotheses
Chen, H., Wang, K., Scheperjans, F., & Killinger, B. A. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105601 · Cited by 44 · see citing works
Self-citationMolecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease
Долгачева, Л. П., Зинченко, В. П., & Goncharov, N. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113043 · Cited by 41 · see citing works
Neurodegenerative Microbially-Shaped Diseases: Oxidative Stress Meets Neuroinflammation
Silva, D. F., Empadinhas, N., Cardoso, S. M., & Esteves, A. R. (2022) · Antioxidants · doi:10.3390/antiox11112141 · Cited by 39 · see citing works
Parkinson’s Disease and Photobiomodulation: Potential for Treatment
Bicknell, B. T., Liebert, A. D., & Herkes, G. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010112 · Cited by 37 · see citing works
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36 · see citing works
Dysbiosis in Parkinson’s disease might be triggered by certain antibiotics
Ternák, G., Kuti, D., & Kovács, K. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109564 · Cited by 35 · see citing works
Zacharias, H. U., Kaleta, C., Cossais, F., Schaeffer, E., Berndt, H., Best, L., Dost, T., Glüsing, S., Groussin, M., Poyet, M., et al. (2022) · Metabolites · doi:10.3390/metabo12121222 · Cited by 36 · see citing works
Tan, L. Y., Yeo, X. Y., Bae, H., Lee, D. P. S., Ho, R., Kim, J. E., Jo, D., & Jung, S. (2021) · Life · doi:10.3390/life11070698 · Cited by 34 · see citing works
Epidemiology of Parkinson’s disease
Катунина, Е. А., Putyatin, I. A., Dzugaeva, F. K., & Batsoeva, D. O. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202512511239 · Cited by 33 · see citing works
Genetic overlap between Parkinson’s disease and inflammatory bowel disease
Kang, X., Ploner, A., Wang, Y., Ludvigsson, J. F., Williams, D. M., Pedersen, N. L., & Wirdefeldt, K. (2022) · Brain Communications · doi:10.1093/braincomms/fcad002 · Cited by 32 · see citing works
Liebert, A. D., Bicknell, B. T., Laakso, E., Jalilitabaei, P., Tilley, S., Kiat, H., & Mitrofanis, J. (2021) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1089/photob.2021.0056 · Cited by 31 · see citing works
Schmit, K. J., Garcia, P., Sciortino, A., Aho, V. T. E., Rodriguez, B. P., Thomas, M. H., Gérardy, J., Acha, I. B., Halder, R., Cialini, C., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113071 · Cited by 31 · see citing works
van Vuuren, M. J., Nell, T. A., Carr, J. A., Kell, D. B., & Pretorius, E. (2020) · Biomolecules · doi:10.3390/biom11010030 · Cited by 31 · see citing works
Microbiome-based therapeutics for Parkinson's disease
Hamilton, A. M., Krout, I. N., White, A. C., & Sampson, T. R. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00462 · Cited by 31 · see citing works
Towards early detection of neurodegenerative diseases: A gut feeling
Makdissi, S., Parsons, B., & Cara, F. D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1087091 · Cited by 27 · see citing works
Cheng, G., Hardy, M., Hillard, C. J., Feix, J. B., & Kalyanaraman, B. (2024) · Communications Biology · doi:10.1038/s42003-024-06330-2 · Cited by 28 · see citing works
Yadav, S., & Raj, R. G. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.07.003 · Cited by 24 · see citing works
Modulation of the Microbiome in Parkinson's Disease: Diet, Drug, Stool Transplant, and Beyond
Brown, E. G., & Goldman, S. M. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00942-2 · Cited by 24 · see citing works
Bacterial, Gut Microbiome-Modifying Therapies to Defend against Multidrug Resistant Organisms
Feehan, A. K., & Garcia‐Diaz, J. (2020) · Microorganisms · doi:10.3390/microorganisms8020166 · Cited by 23 · see citing works
How Toll-like receptors influence Parkinson’s disease in the microbiome–gut–brain axis
Zhang, Z., Liu, Z., Lv, A., & Fan, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1154626 · Cited by 21 · see citing works
Gorecki, A. M., Bakeberg, M. C., Theunissen, F., Kenna, J. E., Hoes, M. E., Pfaff, A. L., Akkari, P. A., Dunlop, S. A., Kõks, S., Mastaglia, F. L., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.603849 · Cited by 21 · see citing works
Hill, A. E., Wade‐Martins, R., & Burnet, P. W. J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.708587 · Cited by 19 · see citing works
Exploring Risk and Protective Factors in Parkinson’s Disease
Beheshti, I. (2025) · Cells · doi:10.3390/cells14100710 · Cited by 18 · see citing works
Mertsalmi, T. H., But, A., Pekkonen, E., & Scheperjans, F. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202330 · Cited by 18 · see citing works
Self-citationTernák, G., Németh, M., Rozanovic, M., Márovics, G., & Bogár, L. (2022) · Antibiotics · doi:10.3390/antibiotics11091145 · Cited by 18 · see citing works
The Role of The Gut Microbiome in Parkinson’s Disease
Gallop, A., Weagley, J. S., Paracha, S.-U.-R., & Grossberg, G. T. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887211018268 · Cited by 17 · see citing works
Kim, C.-H., Jung, J., Lee, Y.-U., Kim, K.-H., Kang, S., Kang, G., Chu, H., Kim, S., & Lee, S. (2022) · Healthcare · doi:10.3390/healthcare10020302 · Cited by 17 · see citing works
Koponen, M., Paakinaho, A., Lin, J., Hartikainen, S. A., & Tolppanen, A. (2022) · Clinical Epidemiology · doi:10.2147/clep.s381289 · Cited by 16 · see citing works
Walker, A. C., Bhargava, R., Bucher, M. J., Argote, Y. M., Brust, A. S., & Czyż, D. M. (2024) · iScience · doi:10.1016/j.isci.2024.110828 · Cited by 15 · see citing works
Shen, S., Zhang, C., Xu, Y.-M., & Shi, C.-H. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212929 · Cited by 15 · see citing works
Bacteria-Derived Protein Aggregates Contribute to the Disruption of Host Proteostasis
Walker, A. C., Bhargava, R., Dove, A. S., Brust, A. S., Owji, A. A., & Czyż, D. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094807 · Cited by 14 · see citing works
Advances of Mechanisms-Related Metabolomics in Parkinson’s Disease
Zhang, Y., Li, J., Zhang, X. L., Song, D., & Tian, T. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.614251 · Cited by 14 · see citing works
Santos, S., Salinas, I., Almeida, N., & Caicedo, A. (2025) · Engineering Microbiology · doi:10.1016/j.engmic.2025.100222 · Cited by 13 · see citing works
Gonçalves, A. M. R., Pereira-Santos, A. R., Esteves, A. R., Cardoso, S. M., & Empadinhas, N. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7997 · Cited by 13 · see citing works
The role of the gut microbiota in the pathophysiology of mental and neurological disorders
Pusceddu, M. M., & Bas-Prior, J. M. D. (2020) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000255 · Cited by 14 · see citing works
Ren, Z.-Y., Xu, Y., Sun, J.-F., Han, Y., An, L., & Liu, J.-F. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102265 · Cited by 12 · see citing works
Johnson, A. M., Ou, Z.-Y. A., Gordon, R., & Saminathan, H. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106113 · Cited by 11 · see citing works
Jin, X., Wei, J., Min, X., Fan, Y., Yuan, Z., Du, Z., Su, Z., Xun, T., Du, Q., Liang, T., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114185 · Cited by 10 · see citing works
Oral and gut microbiome profiles in people with early idiopathic Parkinson’s disease
Stagaman, K., Kmiecik, M. J., Wetzel, M., Aslibekyan, S. W., Sönmez, T. F., Fontanillas, P., Auton, A., Babalola, E., Bell, R. K., Bielenberg, J., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00630-8 · Cited by 10 · see citing works
Green, J. E., Wrobel, A. L., Todd, E., Marx, W., Berk, M., Lotfaliany, M., Castle, D. J., Cryan, J. F., Athan, E., Hair, C., et al. (2024) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.121 · Cited by 11 · see citing works
Sequestration of Inflammation in Parkinson’s Disease via Stem Cell Therapy
Gordon, J., Lockard, G., Monsour, M., Alayli, A., Choudhary, H., & Borlongan, C. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710138 · Cited by 10 · see citing works
Zhu, H., He, H., Yang, M., Zhu, H., Hagiwara, A., Shu, L., Xu, J., Miao, Y., Han, X., & Wang, C. (2025) · iScience · doi:10.1016/j.isci.2025.114044 · Cited by 8 · see citing works
Oh my gut! Is the microbial origin of neurodegenerative diseases real?
Walker, A. C., & Czyż, D. M. (2023) · Infection and Immunity · doi:10.1128/iai.00437-22 · Cited by 10 · see citing works
Gut microbial dysbiosis aggravated Parkinson-like pathology induced by MPTP/probenecid
Chen, Q.-Z., Shang, J., Jiang, Y., Yang, Y., Zang, C., Ma, J., Dong, Y.-R., Wang, J., Zhou, N., Yang, X., et al. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.115008 · Cited by 7 · see citing works
Effects of antimicrobial exposure on the risk of Parkinson's disease
Pal, G. D., Bennett, L., Roy, J. A., Nyandege, A. N., Mouradian, M. M., Gerhard, T., & Horton, D. B. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107081 · Cited by 6 · see citing works
Bicknell, B. T., Saltmarche, A. E., Hares, O., Herkes, G., & Liebert, A. D. (2023) · Medical Research Archives · doi:10.18103/mra.v12i1.4929 · Cited by 5 · see citing works
Li, X., Hao, X., Chen, C., Zhai, C., Pan, T., Zhou, X., Liu, Y., Wu, D., & Chen, X. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1421270 · Cited by 7 · see citing works
Czyż, D. M. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335788 · Cited by 4 · see citing works
Chi, F., Chen, K., Yin, Y., Hakovirta, J. R., & Saris, P. E. J. (2026) · Sustainable Microbiology · doi:10.1093/sumbio/qvag002 · Cited by 5 · see citing works
Identifying Drugs Associated With Parkinson's Disease Risk Using Machine Learning
Pylkkö, E., Courtois, É., Paakinaho, A., Hartikainen, S. A., Kaasinen, V., Elbaz, A., Thiébaut, A. C. M., Ahmed, I., & Tolppanen, A. (2026) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70192 · Cited by 3 · see citing works
Antibiotic Exposure and Risk of Parkinson Disease in South Korea
Kim, M., Park, S. J., Park, Y. J., Choi, J., Song, J., Kim, H. J., Chang, J., Park, S., Kim, J.-W., Lee, H., et al. (2024) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200400 · Cited by 3 · see citing works
The interplay between gut microbiota composition and dementia
Pour, R. G. K., Zounouzi, S. K., Farshbafnadi, M., & Rezaei, N. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0113 · Cited by 3 · see citing works
Abouelmagd, M. E., Kassar, O., Hassan, A., AbdelMeseh, M., Mady, A., & Makhlouf, H. A. (2025) · Neuroepidemiology · doi:10.1159/000545218 · Cited by 3 · see citing works
Vetrievel, C., Nithyanandam, A., Srinivasan, S., Bharatidasan, S. S., Dedeepiya, V. D., Ikewaki, N., Iwasaki, M., Senthilkumar, R., Preethy, S., & Abraham, S. J. (2023) · medRxiv · doi:10.1101/2023.04.14.23288571 · Cited by 3 · see citing works
Wang, Q.-Q., Sun, Q.-Q., Guo, Y.-S., Yin, S., & Zhou, J. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00571-3 · Cited by 2 · see citing works
Benefits of Helicobacter pylori Eradication on Extragastric Diseases
Kim, T. J., & Lee, H. (2021) · The Korean Journal of Helicobacter and Upper Gastrointestinal Research · doi:10.7704/kjhugr.2021.0041 · Cited by 2 · see citing works
Das Exposom im Fokus präventiver Maßnahmen für die Alzheimer- und Parkinson-Erkrankung
Schäffer, E., & Piel, J. (2023) · Der Nervenarzt · doi:10.1007/s00115-023-01538-9 · Cited by 2 · see citing works
Antibiotic Therapy, Antibiotic Resistance, Drug-Induced Pathomorphosis, and Evolutionary MedicinePreprint
Palyutin, S., & Хохлов, А. Л. (2023) · Preprints.org · doi:10.20944/preprints202306.0244.v1 · Cited by 2 · see citing works
Patel, P., Ebrahim, M. A., & Adler, D. G. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2487142 · Cited by 1 · see citing works
Lounici, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613152 · Cited by 1 · see citing works
Parkinson’s disease and inflammatory bowel disease: exploring the connection between the two
Zhou, X., Zhang, X., Liang, H., & Bi, Y. (2026) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2026.01 · Cited by 1 · see citing works
Antibacterials may increase risk of Parkinson's disease
(2019) · Reactions Weekly · doi:10.1007/s40278-019-72728-3
Multifactor Progression of Parkinson's Disease: Role of Diet and Exposure to Microbiome-Borne CurliPreprint
Schmit, K. J., Sciortino, A., Aho, V. T. E., Garcia, P., Rodriguez, B. P., Thomas, M. H., Gérardy, J., Acha, I. B., Halder, R., Cialini, C., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4182866
Webster, J. L., Eppes, S. C., Lee, B. K., Harrington, N., & Goldstein, N. D. (2024) · medRxiv · doi:10.1101/2024.01.15.24301334
Neurological Disorders and the Gut-Brain Axis
Chattopadhyay, M., Laskar, A., Rahaman, S. S., & Chanda, A. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324549125010010
Birabaharan, M. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf263
Petit, P., Berger, F. R., Bonneterre, V., & Vuillerme, N. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261453798
Balsamo, J. M., & Bess, E. N. (2026) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.6c00110
Frangieh, M. R., Saad, M., Fattouh, N., & Sawan, S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119903
Repurposing existing drugs for Parkinson's disease management
Abouelmagd, M. E., Messak, M., Gadelmawla, A. F., & Kundu, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-54032-5.00007-3
- Authors
- Mertsalmi, T. H., Pekkonen, E., & Scheperjans, F.
- Affiliations
- University of Helsinki (FI)
- Corresponding author
- Scheperjans, Filip
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2019-11-18
- Volume
- 35
- Issue
- 3
- Pages
- 431-442
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2986017919
- Cited by
- 88
- References
- 43
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 15 · 2023: 10 · 2022: 16 · 2021: 18 · 2020: 7 · 2019: 1
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Locations
- Movement Disorders (publishedVersion)
- PubMed (publishedVersion)
- Työväentutkimus Vuosikirja (submittedVersion)
- Funders
- The Academy of Finland (295724, 310835)
- The Finnish Medical Foundation
- The Finnish Parkinson Foundation
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antibiotic Use and Resistance
- Keywords
- Parkinson's disease, antibiotic exposure, gut microbiota, macrolides, lincosamides, tetracycline, sulfonamides, trimethoprim, antifungal agents, broad-spectrum antibiotics, prodromal period, oral antibiotics
- MeSH terms
- Gastrointestinal Microbiome, Anti-Bacterial Agents, Finland, Humans, Parkinson Disease, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
